Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase 3 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 549Carcinoma, Non-Small-Cell Lung 509Prostatic Neoplasms 333Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 262Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 214Lung Neoplasms 207Neoplasm Metastasis 203Carcinoma, Hepatocellular 197Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 133Glioblastoma 132Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 125Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

Etoposide 2Cisplatin 2Carboplatin 2tislelizumab 1durvalumab 1ceralasertib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Extensive Stage Small Cell Lung Cancer × 1 year × Clear all
NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
40 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT04699838 2026-01-02

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Big Ten Cancer Research Consortium

Phase 2 Recruiting
30 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡